This structure offers fundraising flexibility by appealing to two distinct investor types. Some investors prefer the diversified, lower-risk profile of the central hub, while others want direct exposure to a specific high-potential asset or disease area within a subsidiary spoke. This broadens the potential capital pool.
Related Insights
iZora's CEO identifies a "sweet spot" of three to five high-quality programs. This size is large enough to benefit from risk diversification but small enough to avoid losing focus and stretching resources thin. It provides a concrete framework for balancing ambition with manageable execution and capital requirements.
Base intentionally constructs its cap table with a mix of investor types: growth funds for pattern matching, sector funds for domain expertise, strategic partners for market access (e.g., homebuilders), and endowments for long-term stability. This turns the cap table into an active asset beyond just capital.
While multi-stage funds offer deep pockets, securing a new lead investor for later rounds is often strategically better. It provides external validation of the company's valuation, brings fresh perspectives to the board, and adds another powerful, committed firm to the cap table, mitigating signaling risk from the inside investor.
The path from angel to large fund manager doesn't require a traditional start. When personal capital runs out, using SPVs for high-demand deals builds a track record and LP relationships. This deal-driven, bottoms-up approach can organically lead to raising a dedicated fund.
The field of ophthalmology is particularly well-suited for a hub-and-spoke model because it utilizes a wide range of treatment modalities (small molecules, biologics, devices, gene therapy). This allows a central hub to leverage shared expertise in areas like ocular delivery and regulatory pathways across multiple, diverse spokes.
A successful seed fund model is to first build a diversified 'farm team' of 20-25 companies with meaningful initial ownership. Then, after identifying the breakout performers, concentrate heavily by deploying up to 75% of the fund's capital into just 3-5 of them.
A clever strategy for first-time fund managers is to raise smaller checks from a large number of operators and domain experts. While harder to execute, this turns the LP base into a powerful, built-in expert network for diligence and support, converting a fundraising challenge into a strategic asset.
The independent sponsor model allows for longer hold periods, focusing on maximizing a single asset's value. This avoids the fund-driven temptation to sell successful companies prematurely to show a high IRR to LPs for the next fundraising round, capturing more value in the later years of an investment.
Immusoft balances its portfolio by internally developing a pipeline of genetically defined orphan disease therapies. Simultaneously, it generates early proof-of-concept data for higher-risk, larger markets like CNS and oncology with the explicit goal of securing strategic partnerships for those assets.
Mega-funds like a16z operate on a different model than smaller VCs. They provide Limited Partners with diversified, almost guaranteed access to every major tech company, prioritizing strong absolute dollar returns over the high multiples sought from smaller, more concentrated funds.
